Blood NAD+ levels linked to frailty in older adults in Japanese community study

A new study in GeroScience from the Itabashi Longitudinal Study on Aging examined whether whole-blood NAD+ levels—a measure increasingly touted by longevity enthusiasts—actually correlate with real-world health outcomes in older adults. NAD+ (nicotinamide adenine dinucleotide) is a crucial metabolic molecule that declines with age and is central to cellular energy production and DNA repair. The researchers measured blood NAD+ concentrations in community-dwelling Japanese older adults and assessed frailty, a clinical syndrome of increased vulnerability to stressors. They found significant associations: lower NAD+ levels correlated with greater frailty. This matters because it moves NAD+ from theory to practice, demonstrating that this biomarker tracks with functional decline in real human populations, not just lab models. While the study is observational—it can't prove low NAD+ causes frailty or that boosting it helps—it provides important validation for ongoing clinical trials of NAD+ precursors like NMN and NR. The use of whole-blood measurements is particularly relevant since it's more practical than tissue biopsies for clinical monitoring. This adds weight to the idea that NAD+ restoration could be a legitimate intervention target for healthy aging.